Sign inJoin waitlistJoin the waitlist

Theodore Leng

Medical Informatics Director, Ambulatory Specialties, Stanford Health Care · Stanford Health Care

Credentials: · · · · · ·

History

Ophthalmic Artificial Intelligence Summit Department · Stanford Health Care
Present
Stanford Ophthalmic Reading Center (STARC) · Stanford Health Care
Present
Stanford Health Care
Present

Stanford University Retina and Vitreous Fellowship (2010) CA
2009–2010
University of Miami Hospital and Clinics/Bascom Palmer Eye Institute-Anne Bates Leach Eye Center
2006–2009
Huntington Memorial Hospital
2005–2006
Stanford University School of Medicine
2001–2005
Stanford University
1997–2001

Research

Automated Identification of Diabetic Retinopathy Using Deep Learning
Ophthalmology · 2017 · 578 citations
SUNDROP: six years of screening for retinopathy of prematurity with telemedicine
Canadian Journal of Ophthalmology-journal Canadien D Ophtalmologie · 2015 · 136 citations
Progression of Photoreceptor Degeneration in Geographic Atrophy Secondary to Age-related Macular Degeneration
JAMA Ophthalmology · 2020 · 123 citations

Daniel Rubin
25 papers
Darius Moshfeghi
22 papers
Jennifer Lim
14 papers
Durga Borkar
10 papers · 3 as a fellow
Ruwan Silva
8 papers · 4 as a fellow
Atalie Thompson
7 papers
LZ
Luo Zheng
7 papers
Prithvi Mruthyunjaya
7 papers
Rishi Singh
7 papers
Mark Blumenkranz
6 papers
Natalia Callaway
6 papers · 4 as a resident
Peter Karth
6 papers · 4 as a fellow

Clinical trials

Safety and Tolerability of RPE Stem Cell-derived RPE(RPESC-RPE) Transplantation in Patients With Dry Age-related Macular Degeneration (AMD)
Principal investigator · Recruiting · Phase 1, Phase 2
Luxa Biotechnology, LLC
2022–2026
Phase I Study of Episcleral Celecoxib for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole
Principal investigator · Unknown · Phase 1
Targeted Therapy Technologies, LLC
2021–2024
Episcleral Dexamethasone for Treatment of Macular Edema and Inflammatory Disorders of the Posterior Pole
Principal investigator · Unknown · Phase 1
Targeted Therapy Technologies, LLC
2019–2024
A Phase I Study of Episcleral Dexamethasone for Treatment of Macular Edema
Principal investigator · Unknown · Phase 1
Targeted Therapy Technologies, LLC
2019–2024